TSLP Inhibitors
1 drugsAbout TSLP
TSLP (thymic stromal lymphopoietin) is a cytokine that regulates inflammatory pathways, initiating and perpetuating allergic inflammation. As an upstream regulator, it plays a crucial role in the inflammatory cascade.
TSLP is a therapeutic target in respiratory diseases, though there is currently no genetic evidence directly linking TSLP to specific diseases. Its position in the inflammatory cascade makes it an attractive target for intervention.
TSLP is targeted by one approved drug, TEZSPIRE (AstraZeneca), a biologic. This drug addresses unmet needs in respiratory diseases.
Top TSLP Drugs
AstraZeneca is the only company with an approved drug targeting TSLP.
The market is not yet saturated, but AstraZeneca's first-mover advantage creates a barrier to entry.
TSLP Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets TSLP, using biologic (other) modality.
Explore small molecule or alternative modalities to differentiate from existing therapies.
TSLP Clinical Trials 39 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on TSLP. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 6 | 0 | 1 | 100% |
| Phase 2 | 9 | 3 | 1 | 5 | 75% |
| Phase 3 | 21 | 11 | 1 | 9 | 92% |
| Phase 4 | 2 | 1 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
TSLP Drug Approval Timeline (2021 - 2021)
The first and only drug, TEZSPIRE, was approved in 2021.
The recent approval suggests potential for further innovation, but also a risk of rapid market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 12 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on TSLP. A trial counts if an approved drug acting on TSLP is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.